Authorization

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nano-X Imaging Ltd. of Class Action Lawsuit and Upcoming Deadline -- NNOX

NEW YORK, Oct. 17, 2020 /PRNewswire/ --A Pomerantz LLP announces that a class action lawsuit has been filed against Nano-X Imaging Ltd.A ("Nano-X" or the "Company") (NASDAQ: NNOX) and certain of its officers.A A  The class action, filed in United States District Court for the Eastern District of New York, and docketed under 20-cv-04528, is on behalf of a class consisting of all persons other than Defendants who purchased or otherwise, acquiredA Nano-X securities between August 21, 2020 and September 15, 2020, both dates inclusive (the "Class Period").A  Plaintiff seeks to recover compensable damages caused by Defendants' violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act").If you are a shareholder who purchased Nano-X securities during the class period, you have until November 16, 2020, to ask the Court to appoint you as Lead Plaintiff for the class.A  A copy of the Complaint can be obtained at www.pomerantzlaw.com. A  To discuss this action, contact Robert S. Willoughby at newaction@pomlaw.comA or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.A  [Click here for information about joining the class action]A Nano-X purportedly develops and produces x-ray source technology for the medical imaging industry.A  The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational, and compliance policies.A  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that:A  (i) Nano-X's commercial agreements and its customers were fabricated; (ii) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (iii) Nano-X's submission to the U.S. Food and Drug Administration ("FDA") admitted the Nanox System was not original; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Ноябрь 2020    »
ПнВтСрЧтПтСбВс
 1
2345678
9101112131415
16171819202122
23242526272829
30